Get the weekly note
ETFIQetfiq.com · independent ETF data

Data as of .

FBT vs GNOM: which is really different?

FBT and GNOM hold 26% of their weight in the same names, and GNOM returned more over the year.

First Trust NYSE Arca Biotechnology Index Fund and Global X Genomics & Biotechnology ETF.

23.6%FBT in the S&P 500
20.9%GNOM in the S&P 500
+48.9%FBT total return, 1 year
+77.5%GNOM total return, 1 year

ETFIQ Off-Index Score: FBT scores higher

How much of it is not the index it is sold as an alternative to?

FBT 64.1GNOM 44.50.1, the lowest in this set91.8, the highest

A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed

FBT76% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
24%76%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 39% of the fund · 31 holdings filed Sep 18, 2026 · Nasdaq-100: 16% in24%76%inoutside the S&P 500active share 99% · top ten 39% of the fund
GNOM79% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
21%79%in the S&P 500of its weight outside the S&P 500active share 98% · top ten 53% of the fund · 52 holdings filed Sep 18, 2026 · Nasdaq-100: 5% in21%79%inoutside the S&P 500active share 98% · top ten 53% of the fund

26% of the two portfolios are the same securities at the same weight.

What they hold in common

By the books each fund has filed, FBT and GNOM hold 26% of their money in the same securities at the same weight.

Positions FBT and GNOM both hold, largest shared weight first
HoldingFBTGNOM
Natera, Inc.4.24%5.13%
Illumina, Inc.3.90%5.30%
BioMarin Pharmaceutical Inc.3.35%3.41%
Vertex Pharmaceuticals Incorporated3.24%3.35%
Bio-Techne Corporation3.14%3.56%
BioNTech SE (ADR)3.25%2.55%
Veracyte, Inc.2.16%2.33%
Gilead Sciences, Inc.3.58%1.63%
Sarepta Therapeutics, Inc.3.29%1.51%
Bruker Corporation3.17%0.33%
Only in each
Only in FBTOnly in GNOM
Halozyme Therapeutics, Inc. 4.57%MODERNA INC 7.99%
NeoGenomics, Inc. 4.37%TWIST BIOSCIENCE CORP 7.40%
Repligen Corporation 3.80%10X GENOMICS INC-CLASS A 6.53%
Corcept Therapeutics Inc. 3.72%GUARDANT HEALTH INC 5.78%
Genmab A/S (ADR) 3.71%GENSCRIPT BIOTECH CORP 4.29%
Regeneron Pharmaceuticals, Inc. 3.66%QIAGEN N.V. 3.13%
BeOne Medicines Ltd. (ADR) 3.64%CRISPR THERAPEUTICS AG 2.89%
argenx SE (ADR) 3.50%CARIS LIFE SCIENCES INC 2.72%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026.

Performance, window by window

FBT and GNOM over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ.
WindowTotal returnvs the S&P 500vs the Nasdaq-100
FBTGNOMFBTGNOMFBTGNOM
3 months+17.2%+27.6%+14.9 pts+25.4 pts+19.6 pts+30.1 pts
6 months+40.6%+56.4%+22.6 pts+38.4 pts+16.4 pts+32.2 pts
1 year+48.9%+77.5%+32.3 pts+60.9 pts+27.1 pts+55.7 pts
3 years+80.7%+59.3%+2.3 pts−19.1 pts−17.5 pts−38.9 pts
Since launch+848.2%+9.8%+44.6 pts−185.2 pts−842.1 pts−297.4 pts
Open the live comparison on ETFIQ
FBT and GNOM on the same fields, as of Sep 18, 2026. Source: ETFIQ.
FBT
First Trust NYSE Arca Biotechnology Index Fund
Holds 31 stocks in biotech, 24% of its weight in S&P 500 companies
GNOM
Global X Genomics & Biotechnology ETF
Holds 52 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies
IssuerFirst TrustGlobal X
ThemeBiotechGenomics and gene editing
In the S&P 50023.6%20.9%
Active share vs the S&P 50099.1%97.6%
In the Nasdaq-10016.2%5.0%
Holdings3152
Top ten, share of the fund39.2%52.7%
Expense ratio0.55%0.50%
Fee for the differing part0.55%0.51%
Total return, 1 year+48.9%+77.5%
vs the S&P 500+32.3 pts+60.9 pts
vs the Nasdaq-100+27.1 pts+55.7 pts
Below its high−2.1%−39.6%
Net assets$2.9bn$100m

FBT in plain words

By weight, 24% of FBT's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 39% of the fund across 31 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +48.9% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 32.3 pts.

GNOM in plain words

By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 53% of the fund across 52 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +77.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 60.9 pts. It sits 39.6% below its all-time high of Feb 8, 2021.

Questions people ask

Do FBT and GNOM hold the same stocks?
By their latest filings, 26% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, FBT or GNOM?
FBT has 24% of its weight in S&P 500 names and GNOM has 21%, so FBT differs more from the index.
Which is cheaper, FBT or GNOM?
FBT charges 0.55% a year and GNOM charges 0.50%, so GNOM is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

FBT against GNOM, ETFIQ, data as of Sep 18, 2026. Every figure is calculated from a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, FBT against GNOM, data as of Sep 18, 2026. https://etfiq.com/compare/themes/fbt-vs-gnom Free to use with attribution; the underlying files are at Open data.

How every figure is computed · Standards and sources